Evaluating Nicorandil to Prevent Blood Flow Issues During Heart Procedures

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effects of intracoronary nicorandil injection on preventing reduced blood flow in patients undergoing percutaneous coronary intervention for coronary artery disease. It specifically targets patients with high-risk plaque lesions, identified by a high lipid core burden index. The study aims to determine if nicorandil can improve outcomes by maintaining coronary blood flow during stent placement. Participants will be monitored for their response to the treatment and overall procedural success.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Over 19 years old
2. Patients who agree to the study plan and clinical follow-up plan, voluntarily decide to participate in this study, and consent in writing to the consent to use information
3. Patients who underwent NIRS-IVUS guided coronary stent surgery for coronary artery disease
4. maxLCBI4mm ≥354 in the culprit lesion measured by NIRS-IVUS

Exclusion Criteria:

1. Patients with TIMI ≤ 2 before coronary intervention
2. Subjects with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, ticagrelor, prasugrel, rosuvastatin, ezetimibe, evolocumab, lansoprazole, cobalt chromium, stainless steel nickel And contrast agents (however, even a subject who is hypersensitive to contrast agents can register if they can be controlled by steroids and pheniramine, except for known anaphylaxis.)
3. Pregnant women, lactating women, or women of childbearing age who plan to become pregnant during this study
4. Subjects who plan to have surgery to stop antiplatelet drugs within 6 months from registration
5. Those whose surviving life is expected to be less than 1 year
6. Subjects who visited the hospital due to cardiogenic shock and are predicted to have low survival probability based on medical judgment

Where it's running

• Korea University Anam Hospital
  Seoul, South Korea Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Aspirin 50 mg vs 100 mg with a P2Y12 inhibitor after PCI

  This trial tests whether a 50 mg daily aspirin dose, when used with a P2Y12 inhibitor after PCI, works as well as 100 mg with similar safety for people staying on DAPT for 12 months.

  Recruiting Jilin University · Changchun, Jilin · NCT07846462

• Long-term P2Y12 inhibitor monotherapy and blood clotting after angioplasty

  This trial will test whether specific P2Y12 drugs and reduced doses given alone keep platelet activity in a safe therapeutic range for people who completed initial dual antiplatelet therapy after PCI.

  Recruiting Phase 3 Cardiocentro Ticino · Lugano, Ch/ti · NCT07582835

• What affects bleeding control and how long you need to lie flat after femoral arterial sheath removal

  We will see if patient and procedure factors can predict how long ICU patients need compression and bed rest after femoral arterial sheath removal to prevent bleeding and hematoma.

  Recruiting National Taiwan University Hospital · Taipei · NCT07469397

• Doctors' and patients' preferences for PCI implantation devices

  This questionnaire tests what patients who have had PCI and the doctors who treat them prefer between drug-eluting stents and drug-coated balloons.

  Recruiting Xijing Hospital · Xi'an, Shannxi · NCT07378163

• How patients and doctors value different outcomes after coronary stent procedures

  This project asks patients who had a coronary stent (PCI) and the doctors who treat them to rate how important different possible outcomes are to see if their priorities match.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT07378137

• Flozins to prevent contrast-related kidney injury after coronary angiography or PCI

  This project tests whether taking a flozin (empagliflozin or dapagliflozin), short-term or long-term, lowers the chance of contrast-induced acute kidney injury in patients having coronary angiography or PCI.

  Recruiting Collegium Medicum w Bydgoszczy · Bydgoszcz · NCT07231939

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.